伏立諾他|T1583|TargetMol

價格	￥326	￥817	￥1223
包裝	50mg	200mg	500mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-09-23

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:伏立諾他	英文名稱:Vorinostat
CAS:149647-78-9	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.93%	產(chǎn)品類別: 抑制劑
貨號: T1583

Product Introduction

Bioactivity

名稱	Vorinostat
描述	Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis.
細(xì)胞實驗	Cells were plated onto 100-mm tissue culture plates at a density of 2 × 10^6 for 48 h and then treated with SAHA or equal concentrations of the vehicle. For longer drug exposure times, medium with drug or vehicle were exchanged every 48 h. For wash-out experiments, cells were treated with SAHA daily for 60–72 h (drug and medium were exchanged at 48 h), then SAHA was washed out and replaced with 10% FCS containing DMEM [3].
動物實驗	Athymic Nude-Foxn1nu/nu mice were used in the present study. They were housed at 22°C at a constant light-dark cycle (12-h light, 12-h dark) and had free access to water and rodent chow (4-5% fat, 21% protein). Twelve weeks old male mice (n = 14) were anesthetized with Isofluran and 5 × 10^6 MES-SA cells were injected subcutaneously into the right flank of the animal. Mice from a control group received placebo containing 300 μl of empty HOP-β-CD (2-hydroxypropyl-β-cyclodextrin) vesicles. Another group of mice received vorinostat dissolved in HOP-β-CD at a concentration of 50 mg/kg/day. Both, empty vesicles and vorinostat were administered intraperitoneally, starting on the day 4 after the injection of MES-SA tumor cells. Mice body weight and tumor size (w2 × l × 0.52; measured by caliper) were estimated twice a week. All mice were treated for 21 days and afterward sacrificed by cervical dislocation. Each tumor was isolated as a whole and different tumor parameters (weight, volume, size, and macroscopic appearance) were determined. Finally, tumor slices were cryopreserved and formalin fixed (4%) for further analyses [1].
體外活性	方法：滑膜肉瘤細(xì)胞 SW-982 和軟骨肉瘤細(xì)胞 SW-1353 用 Vorinostat (0.5-15 μM) 處理 48 h，使用 MST assay 檢測細(xì)胞活力。結(jié)果：Vorinostat 以劑量依賴的方式抑制 SW-982 和 SW-1353 細(xì)胞增殖，IC50 分別為 8.6 μM 和 2.0 μM。[1] 方法：子宮肉瘤細(xì)胞 MES-SA 用 Vorinostat (3 μM) 處理 24-72 h，使用 Western Blot 方法檢測靶點蛋白表達(dá)水平。結(jié)果：在整個處理期間，HDAC1 的表達(dá)沒有差異。HDAC2、3 和 7 顯示出 Vorinostat 對表達(dá)的顯著抑制。[2]
體內(nèi)活性	方法：為檢測體內(nèi)抗腫瘤活性，將 Vorinostat (50 mg/kg in HOP-β-CD) 腹腔注射給攜帶子宮肉瘤 MES-SA 的 Nude-Foxn1nu/nu 小鼠，每周五次，持續(xù)二十一天。結(jié)果：與安慰劑組相比，Vorinostat 治療組觀察到腫瘤生長減少了 50% 以上。[1] 方法：為研究在真性紅細(xì)胞增多癥 (PV) 動物模型中的作用，將 Vorinostat (200 mg/kg in 50% PEG-400) 腹腔注射給 MxCre;Jak2V617F/+ 小鼠，每周五次，持續(xù)兩周。結(jié)果：Vorinostat 治療使 Jak2V617F 敲除小鼠的外周血計數(shù)正?；?，并顯著減少脾腫大。Vorinostat 可能對 PV 和其他 JAK2V617F 相關(guān)的骨髓增生性腫瘤具有治療潛力。[3]
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	10% DMSO+40% PEG300+5% Tween 80+45% Saline : 12.5 mg/mL (47.29 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Ethanol : 2 mg/mL (7.6 mM) DMSO : 125 mg/mL (472.90 mM), Sonication is recommended.
關(guān)鍵字	Autophagy \| Apoptosis \| Filovirus \| Histone deacetylases \| Human papillomavirus \| inhibit \| HDAC \| Inhibitor \| Mitophagy \| Vorinostat \| MK 0683 \| Mitochondrial Autophagy \| HPV \| MK-0683
相關(guān)產(chǎn)品	Guanidine hydrochloride \| Naringin \| Hydroxychloroquine \| Stavudine \| Paeonol \| Sodium 4-phenylbutyrate \| Phenytoin sodium
相關(guān)庫	抑制劑庫 \| 經(jīng)典已知活性庫 \| 抗癌活性化合物庫 \| 抗癌上市藥物庫 \| 抗衰老化合物庫 \| FDA 上市藥物庫 \| 抗病毒庫 \| 藥物功能重定位化合物庫 \| 抗癌臨床化合物庫 \| 抗癌藥物庫

關(guān)鍵字：伏立諾他|||suberoylanilide hydroxamic acid|||SAHA|||MK0683|TargetMol

公司簡介

上海陶術(shù)生物科技有限公司為美國Target Molecule Corp. ( Target Mol ) 在上海建立的全資子公司。我們與美國波士頓、德國慕尼黑的同事一起，為北美、歐洲和亞洲從事藥物研發(fā)和生物學(xué)研究的科學(xué)家提供優(yōu)質(zhì)的產(chǎn)品和專業(yè)的服務(wù)。公司下設(shè)篩選事業(yè)部，化學(xué)事業(yè)部，生物事業(yè)部和新材料部。從虛擬篩選到實體化合物分子供應(yīng)；從商業(yè)化產(chǎn)品銷售到個性化定制合成；從對明確靶點的分子篩選到對明確分子的多靶點篩選，從高通量篩選到化學(xué)結(jié)構(gòu)優(yōu)化，我們都可以滿足您的科研用品及技術(shù)服務(wù)的需求。經(jīng)過在中國市場五年的精心耕耘，我們已成為篩選化合物領(lǐng)域優(yōu)秀的供應(yīng)商，為超過五百家學(xué)校和各類企業(yè)提供了品質(zhì)卓越的小分子化合物和藥物篩

成立日期	2013-04-18 （12年）	注冊資本	566.2651萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	化學(xué)試劑,生物活性小分子	經(jīng)營模式	貿(mào)易,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 12年

公司成立：12年
注冊資本：566.2651萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑，藥物篩選化合物庫，天然產(chǎn)物，活性分子化合物等
公司地址：上海市閘北區(qū)江場三路28號4樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

其他特殊品種庫

￥5000

其他特殊品種庫

￥5000

托吡卡胺|T1281|TargetMol

￥186